EHA 2024

Melissa BadamoMyelodysplastic Syndromes | November 22, 2024
High circular RNA abundance is correlated with disease progression in patients with MDS.
Patrick DalyMeeting News | November 4, 2024
Isolating CD34-positive samples from patients with MDS was better able to detect molecular relapse.
Melissa BadamoMyelodysplastic Syndromes | November 1, 2024
More patients treated with luspatercept had improvement or resolution of neutropenia and thrombocytopenia, she said.
Advertisement
Valeria Santini, MDMyelodysplastic Syndromes | October 24, 2024
At EHA 2024, Dr. Santini shares data on luspatercept and imetelstat in patients with MDS and anemia.
Melissa BadamoMyelodysplastic Syndromes | September 26, 2024
Dr. Garcia-Manero discussed luspatercept, a first-in-class drug for patients with low-risk MDS and anemia.
Melissa BadamoVideo Insights | July 24, 2024
The SOHO 2024 Annual Meeting will take place September 4-7, 2024, in Houston, Texas.
Advertisement
Melissa BadamoVideo Insights | July 22, 2024
The foundation conducts partnerships with companies to provide funding to accelerate novel blood cancer therapies.
Andrew MorenoMyelodysplastic Syndromes | August 23, 2024
Multivariable analysis in a phase II study linked the supplements to an overall survival benefit in patients.
Melissa BadamoMyeloma | July 24, 2024
Dr. Martin highlighted research in quadruplet therapy, CAR-T therapy, and bispecific T-cell engagers.
Salomon Manier, MD, PhDMyeloma | July 18, 2024
A triplet for multiple myeloma has shown promising safety and efficacy in elderly patients ineligible for transplant.
Christophe Willekens, MDAcute Myeloid Leukemia | July 16, 2024
Christophe Willekens, MD, compares standard dosing venetoclax for AML to seven-day dosing plus azacitidine.
Melissa BadamoMyeloma | July 18, 2024
Linvoseltamab achieved on ORR of 71% and a CR rate of 50% in patients with relapsed or refractory multiple myeloma.
Andrew MorenoMyelodysplastic Syndromes | July 8, 2024
Results from a new analysis reaffirm the initial findings of the global, phase III IMerge trial.
Elias Jabbour, MDVideo Insights | July 8, 2024
The 2024 Society of Hematologic Oncology (SOHO) Annual Meeting will take place September 4-7 in Houston, Texas.
Andrew MorenoMyelodysplastic Syndromes | July 3, 2024
Researchers construct a single MDS classification system which integrates the two major international systems.
Andrew MorenoMyelodysplastic Syndromes | July 2, 2024
The study was a noninterventional based on data collected through November 2023.
Salomon Manier, MD, PhDMyeloma | July 17, 2024
Dr. Manier tells of which new phase III data he finds especially exciting in myeloma care.
Katja Sockel, MDMyelodysplastic Syndromes | October 24, 2024
Dr. Sockel from University Hospital Carl Gustav Carus Dresden discusses recent progress and new directions in MDS management.
Melissa BadamoVideo Insights | June 25, 2024
The SOHO 2024 Annual Meeting will take place September 4-7, 2024, at the George R. Brown Convention Center in Houston, Texas.
Leah SherwoodMyelofibrosis | June 17, 2024
Dr. Rampal, of Memorial Sloan Kettering Cancer Center, discusses his abstract at the EHA 2024 Congress in Madrid, Spain.
Advertisement
Advertisement
Editorial Board